The company's object is the management of its own assets as well as the acquisition, disposal, holding and administration of participations in other companies active in the healthcare market domestically and abroad. Excluded are banking transactions or financial services requiring authorization under the German Banking Act (Kreditwesengesetz). The company is domiciled in Bad Vilbel (Local Court of Frankfurt am Main, HRB 110007) and is classified as a small corporation within the meaning of § 267 (1) HGB. The annual financial statements are prepared in accordance with HGB accounting rules and the company applies the size-related reliefs of §§ 274a and 288 (1) HGB.
die Verwaltung eigenen Vermögens, sowie der Erwerb, die Veräußerung, das Halten und die Verwaltung von Beteiligungen an anderen Unternehmen mit Aktivität im Gesundheitsmarkt im In- und Ausland. Ausgenommen sind Bankgeschäfte oder erlaubnispflichtige Finanzdienstleistungen nach dem Kreditwesengesetz.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Frankfurt am Main Local Court, HRB 110007 (as of 1 November 2026)
| Name | Type | City |
|---|---|---|
| Boris Döbler | Geschäftsführer(in) | Frankfurt am Main |
| Peter Goldschmidt | Geschäftsführer(in) | Frankfurt am Main |
| Company | Location |
|---|---|
 ALIUD PHARMA GmbH | Laichingen |
| BEPHA Beteiligungsgesellschaft für Pharmawerte mbH | Bad Vilbel |
| Hemopharm GmbH | Bad Vilbel |
Source: German Commercial Register (Handelsregister) Frankfurt am Main Local Court, HRB 110007 (as of 1 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | €4,296,156,000 | — | €6,794,880,000 | — |
| 2024 | €4,058,917,000 | — | €6,858,140,000 | 11,649 |
| 2023 | €3,734,843,000 | -€124,125,000 | €6,738,767,000 | 11,714 |
| 2022 | €3,797,207,000 | -€523,684,000 | €7,697,047,000 | 13,225 |
| 2021 | €3,010,315,000 | -€147,237,000 | €8,461,119,000 | 12,567 |
| 2020 | €3,010,315,000 | -€147,237,000 | €8,106,063,000 | 12,339 |
| 2019 | €2,608,563,000 | -€105,376,000 | €7,547,912,000 | 11,121 |
| 2018 | €2,330,824,000 | €62,542,000 | €6,873,711,000 | 10,416 |
| 2017 | €822,102,000 | -€369,140,000 | €6,831,965,000 | 10,176 |
| 2016 | — | €112,490,000 | — | — |
Sign in to download data
Source: German Commercial Register (Handelsregister) Frankfurt am Main Local Court, HRB 110007 (as of 1 November 2026)
| Cost type | Amount | Share |
|---|---|---|
| Cost of Goods Sold | €2,426,181,000 | 64.9% |
| Selling Costs | €873,253,000 | 23.3% |
| Admin Costs | €324,033,000 | 8.7% |
| R&D Costs | €117,479,000 | 3.1% |
